Лерканидипин – антагонист кальция III поколения: особенности клинической фармакологии и применение при артериальной гипертензии

1. Opie LH. Clinical use of calcium channel antagonist drugs. 2th edition. Boston 1990.
2. Преображенский Д.В. Клиническое применение антагонистов кальция. М., 1993.
3. Сидоренко Б.А., Преображенский Д.В. Применение антагонистов кальция в кардиологической практике. М., 1997.
4.Сидоренко Б.А, Преображенский Д.В. Антагонисты кальция. М., 1997.
5. Messerli F. (ed.). The ABC of antihypertensive therapy. 2th edition. Philadelphia 2000.
6. Triggle DJ. Mechanisms of action of calcium channel antagonists. In: Calcium antagonists in clinical medicine. Ed. by M.Epstein. Philadelphia 1998: 1–26.
7. Lűscher ThF, Cosebtino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998; 55 (4): 309–17.
8. Opie LH. Drugs for the heart. 4th edition. Philadelphia, 1995.
9. Elliott HL. Requirements for new calcium antagonists. Research Clin Forums 1994; 16 (1): 9–16.
10. Hansson L. Treatment of elderly hypertensive patients with calcium antagonists. Research Clin Forums 1994; 16 (1): 61–8.
11. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Pressure 1996; 5: 206–8.
12. Nayler WG. Amlodipine. Berlin, 1995;1–273.
13. Преображенский Д.В., Сидоренко Б.А., Шабаева Е.Н. Амлодипин – антагонист кальция третьего поколения. Кардиология. 1998; 2: 66–73.
14. Epstein M. Role of a third generation calcium antagonists in the management of hypertension. Drugs 1999; 57 (Suppl. 1): 1–10.
15. McClellan KJ, Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.
16. Borghi C. Lercanidipine in hypertension. Vascular Health Risk Management 2005; 1: 173–82.
17. Beckey C, Lundy A, Lutfi N. Lercanidipine in the treatment hypertension. Ann Pharmacol 2007; 41: 465–74.
18. Barchielli M, Dolfini E, Farina P et al. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S1–15.
19. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovasc. Pharmacol 1997; 29 (Suppl. 1): S19–24.
20. Van Zweiten PA, Pfaffendorf M. Similarities and differences between calcium antagonists: Pharmacological aspects. J Hypertens 1993; 11 (Suppl. 1): S3–11.
21. Meredith PA. Duration of action and through to peak rations of calcium antagonists. Research Clin Forums 1994; 16 (1): 29–41.
22. Van Zweiten PA, Pfaffendorf M. Pharmacology of dihydropyridine calcium antagonists; Relatiomship between lipophilicity and pharmacodynamic response. J Hypertens 1993; 11 (Suppl. 6): S3–11.
23. Herbette LC, Mason RP, Tulenco T et al. Calcium antagonists and membrane binding – the unique properties of lacidipine. Research Clin Forums 1994; 16 (1): 17–28.
24. Herbette LC, Gaviraghi G, Tulenco T et al. Molecular interaction between lacidipine and biological mechanisms. J Hypertens 1993; 11 (Suppl. 1): S13–9.
25. Белоусов Ю.Б., Тхостова Э.Б. Лаципил. Современный антагонист кальция в лечении артериальной гипертензии. М., 1999.
26. Testa R, Leonardi A, Tajana A et al. Lercanidipine (Rec 15/2375): a novel 1,4-dihydropyridine calcium antagonist for hypertension. Cardiovasc Drug Reviews 1997; 15 (3): 187–219.
27. Brixius K, Gross T, Tossios P et al. Incresed vascular selectivity and prolonged pharmacological efficacy of the L-type CA2+ channel antagonist lercanidipine in human cardiovascular tissue. Clin Exper Pharmacol Physiol 2005; 32: 708–13.
28. Guarneri L, Sironi G, Angelico P et al. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997; 29 (Suppl. 1): S25–32.
29. Rossoni G, Bernareggi M, De Gennaro Colonna V et al. Lercanidipine protects the heart from low-flow ischemia damage and antagonizes the vasopressor activity of endothelin-1. J Cardiovasc Pharmacol 1997; 29 (Suppl. 1): S41–7.
30. Cargnoni A, Benigno M, Ferrari F et al. Effects of lercanidipine and its enantiomers on ischemia and repefusion-1. J Cardiovasc Pharmacol 1997; 29 (Suppl. 1): S48–62.
31. Barbagallo M, Sangiorgi GB. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.
32. Ambrosioni E, Circo A. Activity of lercanidipine administrated in single and repeated doses once daily as monitored over 24 hours in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S16–20.
33. Meredith PA. Role of through to peak efficacy in the evaluation of antihypertensive efficacy J Hypertens 1998; 16 (Suppl. 1): S59–64.
34. Circo A. Active dose findings for lercanidipine in double-blind, placebo-controlled design in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S21–5.
35. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison and in combination with atenolol in patients with mild to moderate hypertension in double-blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26–30.
36. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in comparison and in combination with atenolol in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc. Pharmacol 1997; 29 (Suppl. 2): S31–5.
37. Sangiorgi GB. Putignano E, Calcara L, Barbagallo M. Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S36–9.
38. Ninci MA., Magliocca R, Malliani AB. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S40–4.
39. Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50–3.
40. Rengo F, Romis L Activity of lercanidipine in double-blind comparison with nitrendipine in combinition treatment of resistant essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S54–8.
41. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanipine in daily clinical practice. The ELYPSE study. Blood Pressure 2002; 11: 95–100.
42. Cherubini A, Fabris F, Cucinotta D et al. Comparative effects of lercanidipine, lacidipine, and nidedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly of LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 37: 203–12.
43. Marx A, Lichenthal A, Milbredt C et al. Effect of antihypertensive therapy with new third generation calcium antagonist lercanidipine in patients with comcomicant diseases. J Hypertens 2003; 22 (Suppl. 2): S236.
44. Fogari R, Migulelini A, Conradi L et al. Effecacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients. J Hypertens 2000: 18 (Suppl. 2): S65.
45. Vestra MD, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion in hypertensivew type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertesione, Albuminuria, Lercanidipina). Diab Nutr Metab 2004; 17: 259–66.
46. Robles NR, Ocon J, Gomez. CF et al. Lercanidipine in patients with chronic renal failure: The ZAFRA study. Renal Failure 2005; 1: 71–80.
47. Borghi С, Prandin MG, Dormi A et al. The use of lercanidipine can improve the individual tolerability in dihydropyridine calcium blockers in hypertensive patients. J Hypertens 2000; 18 (Suppl. 2): S155–56 (abstract).
48. Pruijum MT, Maillard, Burnier M. Patient adherence and the choice of antihypertensive drugs: focus on lercanipine. Vasc Health Risk Management 2008; 4: 173–82.
49.Barrios V, Escobar C, de la Figuera M et al. Tolerability of high doses of lercanidipine versus high doses of other dihydrohypidine in daily clinical practice. The TOLERANCE. Cardiovascr Ther 2008; 26: 2–9.

Д.В.Преображенский, Н.И.Некрасова, И.Д.Вышинская, А.Ж.Арыстанова 

ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ